JP2003095941A - Sugar digestion enzyme inhibitor, hyperglycemia inhibitor, therapeutic or prophylactic agent for obesity, therapeutic or prophylactic agent for diabetes, and healthy food and drink - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide new applications of a specific component derived from an extract of Lagerstroemia speciosa, more precisely, to provide new applications based on α-amylase inhibitory activity of the component. SOLUTION: A sugar digestion enzyme inhibitor containing valoneaic acid as an active ingredient is proposed based on such information that the valoneaic acid obtained by subjecting the extract of the Lagerstroemia speciosa to separation through liquid-liquid partition, column chromatography, or the like, has the excellent α-amylase inhibitory activity. Because the α-amylase is such an enzyme as especially effective for breaking α-1,4 bonds of starch and glycogen, the inhibitor prevents digestion and absorption of the starch and the glycogen. Therefore, rapid increase in a blood sugar level after a meal is prevented and secretion of insulin is controlled by the inhibitor, so that the inhibitor is effective for treating and preventing diabetes, and inhibiting obesity.

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a new use of a specific component derived from banaba, more specifically to a new use relating to carbohydrate digestive enzyme activity, elevated blood sugar level, obesity, diabetes and the like.

[0002]

BACKGROUND OF THE INVENTION Banaba (Lagerstroemia speciosa (L.) Pers.) Is a kind of crape myrtle that is distributed in tropical Asia and belongs to the family Myrtaceae, also known as L. persica. This boiled juice of leaves and flowers has long been taken as a therapeutic drug for diabetes in the Philippines and other countries, and recently in Japan, attention has been paid to its diabetes therapeutic effect and blood sugar level suppressing effect, and the number of people who drink it as health tea etc. is increasing. There is.

Regarding the pharmacological effect of banaba, in the 1940s, as a result of administration of the decoction of dried banaba leaves to normal rabbits, the blood glucose level was 16 to 49 mg / dose at a dose of 1 to 2 g of dried leaves / kg of body weight. It has been reported that dl could be lowered (F. Garcia: On the hypoglycemic effe
ct of decoction of Lagerstroemia speciosa (Banaba)
J.Philip.Med.Assoc. 20,395 (1940)).

Further, JP-A-5-310587 discloses that a type II diabetic mouse is administered with a diet in which 3% of Banaba extract powder extract is mixed for 1 week, and then 5% of Banaba extract powder extract is administered.
As a result of breeding the mixed diet for 3 weeks, it was disclosed that the blood sugar level of the group that ingested the banaba extract powder extract was significantly suppressed,
Japanese Unexamined Patent Publication No. 9-227398 describes a banaba leaf dry pulverized product
It is disclosed that a sample obtained by concentrating under reduced pressure an extract obtained by adding 00 times amount of 50% ethanol and heating and refluxing for 1 hour, that is, a banaba leaf extract exerted an inhibitory effect on amylase and lipase, and banaba leaf. Extracts for treatment of obesity, diabetes, hyperlipidemia, arteriosclerosis, acne, dermatitis, etc.
It discloses the knowledge that it is useful for prevention.

Regarding the main mechanism of the blood sugar lowering action of banaba, it was confirmed that banaba has an enzyme activity inhibiting action of α-amylase which is a starch digestive enzyme, in addition to the above-mentioned JP-A-9-227398. As a result (Journal of the Japanese Society of Agricultural Chemistry, 1997 Mar. 71), it inhibits the saccharide decomposition in the ingested food and drink by the inhibitory action of the carbohydrate digestive enzyme,
The mechanism of action that delays the absorption of monosaccharides from the intestinal tract and suppresses the rise in blood glucose levels has become uncertain. By the way,
In the medical field, digestive enzyme inhibitors are already used as antiobesity agents and antidiabetic agents.

[0006] Therefore, the present inventor investigated the banaba extract with an inhibitory activity of α-amylase, which is one of the typical digestive enzymes, as a result, and found that a certain specific component in the banaba extract had a strong activity. The present invention has been accomplished based on such knowledge.

[0007]

[Means for Solving the Problems] As a result of detailed examination of α-amylase inhibitory activity of banaba extract component, α-amylase inhibitory activity excellent in fractions obtained by separating banaba extract by liquid-liquid partitioning and column chromatography The present invention has led to the discovery of the present invention, identification of the relevant fraction as baroneaic acid, and the present invention based on such findings.

That is, the present invention proposes a sugar digestive enzyme inhibitor containing baroneaic acid as an active ingredient.

Baroneaic acid is represented by the following formula.

[0010]

[Chemical 2]

[0011] Further, baroneaic acid glycosides, that is, glycosides having a basic skeleton of baroneaic acid, are decomposed into baroneaic acid in the body, so that a sugar digestive enzyme inhibitor containing baroneaic acid glycosides as an active ingredient is also available. It can be considered that the same effect is exhibited.

Therefore, the present invention proposes a sugar digestive enzyme inhibitor containing baronea acid glycoside as an active ingredient. At this time, the baroneaic acid glycoside has the following formula (wherein R1 to R4
Is a sugar, and the rest of R1 to R4 is a hydrogen atom, a functional group having 1 or more carbon atoms, or a sugar. ).

[0013]

[Chemical 3]

The carbohydrate digestive enzyme inhibitor of the present invention inhibits the enzymatic activity of a carbohydrate digestive enzyme, particularly α-amylase. α-
Amylase is an enzyme that arbitrarily cleaves α-1,4 bonds of starch (amylose, amylopectin) and glycogen. By inhibiting the activity of this digestive enzyme and inhibiting its digestion and absorption, it is possible to control the rapid rise in postprandial blood glucose level and also the secretion of insulin, which is effective in the treatment and prevention of diabetes and the prevention of obesity. To do. Therefore, the present invention also proposes a blood glucose elevation inhibitor, an obesity treatment preventive agent, a diabetes treatment preventive agent, which contains any one of baroneaic acid and baroneaic acid glycoside or a mixture thereof as an active ingredient.

In addition to the above-mentioned effects, the carbohydrate digestive enzyme inhibitor, blood sugar level elevation inhibitor, obesity treatment preventive agent, diabetes treatment preventive agent of the present invention have myocardial infarction, arteriosclerosis and hypertension caused by overnutrition. It can be expected to be effective in treating and preventing cardiovascular diseases such as the following, skin diseases such as acne and pimples, and other diseases. It is also useful in terms of safety. Banaba can be safely taken because it has been used regularly in the Philippines and elsewhere, and is particularly suitable for continuous intake. Therefore, in addition to long-term intake for the basic treatment of the above diseases and daily intake for prevention, it is also useful as a diet food, a physical condition-improving food and drink, and the like. In addition, since it is also effective for animals other than humans, blood sugar elevation suppressants for pets, livestock, and other animals, diabetes treatment / prevention agents,
It is also useful as a material and raw material for obesity preventive agents, diet pet food, diet feed and the like.

Since the active ingredient of the present invention inhibits the enzymatic activity of α-amylase as described above, it is added to foods (beverages such as tea drinks, soups, miso soups, etc.) that can be taken with or before and after meals. , Rice, bread, added to foods containing a lot of starch such as noodles to produce healthy foods and drinks, foods and drinks for suppressing blood sugar level increase, foods and drinks for preventing and treating diabetes, foods and drinks for preventing and treating obesity, diet foods and drinks, It can be variously provided as a diet pet food or diet feed.

[0017]

BEST MODE FOR CARRYING OUT THE INVENTION Embodiments of the present invention will be described below.

The sugar digestive enzyme inhibitor, the blood sugar level increase inhibitor, the obesity treatment preventive agent, the diabetes treatment preventive agent of the present invention (hereinafter, these are collectively referred to as "sugar digestive enzyme inhibitor and the like").
Can be produced by blending baroneaic acid, baroneaic acid glycoside, or a mixture of baroneaic acid and baroneaic acid glycoside.

Baroneaic acid and baroneaic acid glycoside can be obtained by extraction and purification from banaba and other plants.

As the solvent used for extraction, water, warm water, hot water, alcohols such as methanol and ethanol, ketones such as acetone, and other organic solvents, or a mixed solution of two or more of these is used. It is possible. Considering human or other animal ingestion, water, ethanol, or acetone is preferable. The extraction conditions such as the ratio of the plant to the extraction solution at the time of extraction, the extraction temperature, the extraction time, etc. may be arbitrarily adjusted depending on the plant to be extracted and the extraction solvent. And
The plant extract obtained by the extraction may be further purified by an adsorbent treatment method, a membrane separation method, or a solvent fractionation method, or a purification method such as such that the content concentration of baroneaic acid or baroneaic acid glycoside is increased. Good.

Here, a method for extracting and purifying "banaba" to obtain baroneaic acid and a glycoside of baroneaic acid will be described.

Banaba or Lagerstroemia speciosa
(L.) Pers. Is a plant belonging to the family Myrtaceae of the order Pleurotus, and its leaves, flowers, or these and stems, xylem,
Mixtures of either roots or fruits can be used for extraction. However, since Banaba contains an extremely large amount of various bacteria, it is necessary to sufficiently perform heat sterilization such as autoclave sterilization before performing the extraction treatment. In particular, Patent No. 281
As in the patented invention described in No. 8458, it is preferable that the dried and crushed Banaba leaf is heat-sterilized, then temporarily stored in a bacterial culture environment, and then heat-sterilized.

Banaba, which has been sterilized by heating, contains water (including hot water),
Extraction may be performed with ethanol or acetone, and then the extract obtained by the extraction may be separated by liquid-liquid partitioning, column chromatography and the like to purify baroneaic acid and baroneaic acid glycoside. At this time, it is preferable to use acetone as the extraction solvent as shown in the following test, and the extraction conditions are not limited, but the extraction solvent is 5 to 100 volumes in terms of extraction operation and efficiency, and the extraction temperature is 50 ° C. ~ It is desirable to perform extraction at a boiling point for about 1 minute to 3 days. When used for beverages, it is preferable to appropriately set the extraction conditions in consideration of the extraction status of the active ingredient and the taste of the extraction liquid itself. For liquid-liquid partitioning and preparative separation by column chromatography, for example, the extract is redissolved in water and sequentially partitioned with ethyl acetate and butanol to obtain an “ethyl acetate phase”.
The "butanol phase" and the "aqueous phase" are obtained, and the "ethyl acetate phase" therein may be separated by column chromatography.

The active ingredients of the present invention, namely baroneaic acid, baroneaic acid glycosides and mixtures thereof, can be used alone as the active ingredients of the present invention. It is possible to synergistically enhance the digestive enzyme activity inhibitory action by combining it with a substance or the like to obtain an active ingredient. As a conventionally known digestive enzyme activity inhibitor, for example, a proteinaceous substance extracted from wheat (MDO'Donnell et.al., Biochemi.
Biophys. Acta 422 (1976) 159-169), polysaccharide derived from soybean (JP-A-3-290187), taro (Colocasi)
a esculenta), a proteinaceous substance NSAI-I extracted from
NSAI-II (Japanese Patent Application No. 2-95992), Laurel (Laur
crude extract extracted from us nobilis L. (Japanese Patent Application No. 2-1)
30852), as well as digestive enzyme activity-inhibiting substances derived from natural products such as wheat albumin, mulberry alkaloids, sulfur-containing processed products of Euphorbiaceae plants, and Nanbankarasuuri. When blended as a single active ingredient, for example, barone acid, barone acid glycoside or a mixture thereof may be dissolved in purified water or physiological saline to be provided as a drug (orally administered drug) or the like. You can

Any of the carbohydrate digestive enzyme inhibitors and the like of the present invention can be used as an orally-administered agent, and in this case, it is preferable that the formulation and dosage form are suitable for each administration. With respect to the dosage form, it can be prepared for oral administration in the form of liquid, tablet, powder, granule, dragee, capsule, suspension, emulsion, pill and the like. Speaking of formulation (formulation), commonly used excipients, fillers, binders,
Manufactured by a conventional method using a wetting agent, a disintegrating agent, a surface active agent, a lubricant, a dispersant, a buffer, a preservative, a solubilizing agent, a preservative, a flavoring agent, a soothing agent, a stabilizer and the like. be able to. Also, for example, lactose, fructose, glucose, starch, gelatin, magnesium carbonate, synthetic magnesium silicate,
Talc, magnesium stearate, methyl cellulose, carboxymethyl cellulose or its salt, gum arabic, polyethylene glycol, syrup, petrolatum, glycerin, ethanol, propylene glycol,
It is also possible to add non-toxic additives such as citric acid, sodium chloride, sodium sulfite and sodium phosphate.

Further, the carbohydrate digestive enzyme inhibitor and the like of the present invention are
In addition to drugs, quasi-drugs, health foods / health drinks / foods with specified health benefits / functional foods, food additives with pharmacological effects, and other non-human animal drugs, feeds, feed additives, etc. You can also do it. For example, it can be made easier to ingest by preparing it as a quasi-drug and making it into a drinkable form such as a bottled drink, or a tablet, capsule, granule or the like. Health foods, health drinks, foods for specified health use, with pharmacological effects
Functional foods include, for example, carbon dioxide, excipients (including granulating agents), diluents, or further sweeteners, flavors, flour, starch, sugars, various proteins such as fats and oils, sugars. Mixtures with one or more selected from food and drink ingredients such as quality raw materials, vitamins and minerals, or currently known food and drink, such as sports drinks,
Fruit drinks, milk drinks, tea drinks, vegetable juices, dairy drinks,
Alcoholic drinks, jellies, jelly drinks, carbonated drinks, chewing gum, chocolate, candy, biscuits,
It can be produced by adding it to snacks, breads, dairy products, fish meat products, livestock products, frozen desserts, dried foods, supplements, pet foods, feeds and the like.

The carbohydrate digestive enzyme inhibitor and the like of the present invention may be taken in advance before meals in order to prevent troubles and diseases caused by overnutrition such as obesity and diabetes, but they may be taken at the same time as meals. Or even if you take it after eating,
Also, it may be mixed with meals and ingested.

The intake amount of the present invention is determined by the method of use, administration method,
Although it depends on the severity of the illness, the age of the human or animal to be ingested, generally speaking, as a drug, baroneaic acid is 20 mg per day as an active ingredient for adults.
-1,000 mg, 6 mg-300 mg for children is preferred, and 40 mg-2,000 mg of baroneaic acid and its glycosides as active ingredients per day for adults and 12 mg-600 mg for children are preferred. The concentration of the active ingredient as a drug is 0.01 to 10% by weight, particularly 0.1 to 5% by weight, in terms of dry weight of baroneaic acid. Converted to 0.004 to 40% by weight, and especially 0.
It is preferably from 04 to 20% by weight. On the other hand, except for medicines, baroneaic acid is 20 mg to 500 mg per day as an active ingredient for adults and 6 mg for children.
An intake of ~ 150 mg is preferable, and as for baroneaic acid and its glycosides, 40 mg to 1,000 m for adults
g, for children, an intake amount of 12 mg to 300 mg is preferable. The effective concentration of baroneaic acid is 0.01 to 5% by weight in terms of dry weight, preferably 0.1 to 2% by weight, and baroneamic acid and its glycoside are preferably in the range of 0. 004 to 20% by weight, especially 0.04 to
It is preferable to add 8% by weight.

(Health Food and Beverage) The health food and beverage of the present invention contains baroneacetic acid, baroneaic acid glycoside, or a mixture thereof, starch (amylose, amylopectin) and other sugars having an α-glucoside bond. Preferably, it can be produced by adding the sugar to a food or drink material containing the sugar as a main ingredient.

Baroneaic acid and baroneaic acid glycoside in this case can be obtained by the same method as described above.

The saccharide having an α-glucoside bond may be a saccharide other than starch (amylose, amylopectin). In short, since the active ingredient of the present invention inhibits the enzymatic activity of α-amylase acting on α-glucoside bond, a sugar having an α-glucoside bond can prevent digestion / absorption of the sugar.

Examples of food and drink materials containing or containing a sugar having an α-glucoside bond are beverages such as vegetable / fruit juice, tea, dairy drinks, dairy drinks and alcoholic drinks, processed seafood, dairy products, Examples include cooked products such as curry and stew, rice, noodles, confectionery, bread, ice cream, pet food, and feed. Further, not only foods and drinks containing a large amount of starch, but also teas, beverages, soups, miso soup, etc., which are ingested during meals are preferable.

In the preparation of healthy foods and drinks, various proteins such as bulking agents, excipients, carbonic acid, excipients (including granulating agents), diluents, sweeteners, flavors, oils and fats, etc. are prepared according to a conventional method. It is optional to add a base such as vitamins and minerals, which is acceptable in the production of foods and drinks, foods and the like. The concentration of active ingredients in healthy food and drink is 0.1-2% by weight.
Is preferred.

Since the health food of the present invention can inhibit the digestion and absorption of foods and drinks that are routinely ingested, the foods and drinks that are routinely taken are diet foods and foods and drinks for diabetics. , Other constitution improving foods and drinks can be easily improved. In particular, as a diet food, a great effect can be expected in that it is possible to diet while eating.

The above-mentioned pharmaceuticals, quasi-drugs, health foods / health drinks / foods for specified health use / functional foods, food additives having other pharmacological effects, other drugs for humans other than humans, feeds, feed additives In agents and the like, the method for quantifying baroneaic acid is preferably a method for quantitatively analyzing baroneaic acid itself using high performance liquid chromatography. (Separation conditions:
Gradient method, solution A: acetonitrile / water / acetic acid = 5/95
/0.1, B solution: acetonitrile / water / acetic acid = 50/50 / 0.1, column: YMC J'sphere-H80, measurement wavelengths: 254 and 350 nanometers). On the other hand, a method of measuring the polyphenol content is useful for the quantification method of baroneaic acid glycoside.
The measuring method is not particularly limited as long as it has a scientific basis,
Particularly, the iron tartrate colorimetric method, which is adopted as an official analytical method in the analysis of polyphenols such as tea, is preferable because it is simple and reliable.

The structure and effects of the present invention will be discussed below based on tests.

(Preparation of test material) An appropriate amount of Philippine Banaba leaves were naturally or forcibly dried and sterilized, and the dried and sterilized Banaba leaves were crushed with a crusher, and 10 g of the obtained crushed Banaba leaves were heated. Extract with 100mL at 85 ℃ for 15 minutes,
The obtained extract was filtered, cooled and freeze-dried to obtain a "hot water extract".

On the other hand, 1 kg of dried and sterilized Banaba leaf is used as 8
It was extracted twice with 3 L of 0% hydrous acetone at room temperature, and the obtained extract was concentrated to obtain an "acetone extract". The "acetone extract" was further dissolved in water and then sequentially partitioned with ethyl acetate and butanol to obtain "ethyl acetate phase", "butanol phase" and "water phase". For the “ethyl acetate phase”, after adsorbing it on a column (MCI gel, 20 × 300 mm),
Elution was performed with 70% ethanol and 100% ethanol with a column volume of 4 times. Column chromatography of 70% ethanol fraction (Sephadex LH20, 20 x 300 mm)
After separation with, the developing solvent is ethanol / methanol (10
0: 0 to 0: 100) and sequentially eluted using Table 1 below.
“Ethyl acetate-1 to 7” was obtained. And further, "ethyl acetate-4 (ethanol / methanol = 40:60)"
For high performance liquid chromatography (C18, Capce
ll Pak, 20 × 300 mm, developing solvent 30% ethanol / 0.
Isolation with 1% acetic acid at a flow rate of 8 mL / min) yielded "ethyl acetate-4-1 (later identified as baroneaic acid.)" In Table 2 below, while concentrating eluates other than baroneaic acid.
It was freeze-dried to obtain "ethyl acetate-4-2".

(Evaluation of activity of active ingredient) The α-amylase inhibition test was measured according to the method of Klein et al. That is, as an enzyme, α-amylase derived from pig pancreatic juice (Sigma
Was used as the substrate, and Starch azure (made by Sigma) was used as the substrate.
3. 200 mg substrate and 4. 25 mL Erlenmeyer flask.
A 40 mM phosphate buffer solution (pH 7.0) containing 5 mL of 20 mM sodium chloride was added, and the mixture was kept at 40 ° C. Fifty
200 μg / ml of μL enzyme solution and 50 μL sample
Or add to 100 μg / ml and shake (8
The reaction was performed for 15 minutes (0 stroke / min). On this occasion,
2 for the samples in Table 1 below (ethyl acetate-1 to 7 etc.)
100 μg / ml for the samples shown in Table 2 below (ethyl acetate-4-1 and 2 etc.).
Was added. After adding the sample as described above, 2.
The reaction was stopped by adding 4 mL of 100 mM phosphate buffer (pH 4.3), the contents of the flask were well stirred, transferred to a 15 mL centrifuge tube, centrifuged, and the supernatant 625
The absorbance at nm is measured and the following formula (KleinB, Foreman JA,
Searcy RL (1969) The synthesis and utilization of c
ibachron blue-amylase: A new chromogenic substrate
for determination of amylase activity. Anal Bioche
m 31: 412-25), the α-amylase inhibition rate (%) was determined.

[0040]

[Equation 1]

In the above equation, A: Absorbance of control solution without addition of sample solution B: blank of control solution C: Absorbance of sample solution D: Blank of sample solution Is.

[0042]

[Table 1]

[0043]

[Table 2]

"Ethyl acetate-4-1" having the highest amylase inhibition rate (%) among the above fractions was subjected to instrumental analysis and found to be "baroneaic acid". In addition, the instrumental analysis at this time is as follows: Separation condition: gradient method, solution A: acetonitrile / water / acetic acid = 5/95 /
0.1, B solution: acetonitrile / water / acetic acid = 50/50
/0.1, column: C18 reverse phase column (YMC J'sphere-H
80, measurement wavelength: 254 and 350 nm, flow rate 1 ml /
min).

(Example 1) A mixed solution containing baroneaic acid, vitamin C and baking soda was heated to 95 ° C again, filled in a can and sterilized by retort, and a sugar digestive enzyme inhibitor having the following composition and suppression of blood sugar level increase were prepared. An agent, an obesity treatment preventive agent, or a diabetes treatment preventive agent was prepared.

[0046] Total volume 200 mL Banaba extract containing baroneaic acid 300 mg Vitamin C ... 40 mg Baking soda ・ ・ 40mg Perfume ・ ・ Appropriate amount Water

Example 2 A mixed solution of baroneaic acid and a mixture of baroneaic acid glycosides, vitamin C and baking soda was heated again to 95 ° C., filled in a can and sterilized by retort, and a sugar-digesting enzyme having the following composition. An inhibitor, a blood glucose elevation inhibitor, an obesity treatment preventive agent, or a diabetes treatment preventive agent was prepared.

[0048] Total volume 200 mL Baroneaic Acid and Baroneaic Acid Glycoside Mixture ... 100mg Vitamin C ... 40 mg Baking soda ・ ・ 40mg Perfume ・ ・ Appropriate amount Water

Example 3 A healthy food / beverage (juice) was prepared with the following composition.

[0050] Total volume 200 mL Baroneaic acid: 50 mg Mandarin orange juice 20g 20g sucrose Citric acid 2g Vitamin C ··· Perfume ・ ・ Appropriate amount Water

Example 4 A healthy food / beverage (bread) was prepared with the following composition.

[0052] Baroneaic Acid and Baroneaic Acid Glycosides-600mg Strong powder ... 300g 15g sugar 6g salt Skim milk ... 6g Dry yeast 6g Water: 195g Shortening: 15g

─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. ⁷ Identification code FI theme code (reference) A61K 35/78 A61P 3/04 4C088 A61P 3/04 3/06 3/06 43/00 111 43/00 111 C07D 493/06 C07D 493/06 C12N 9/99 C12N 9/99 C07H 13/08 // C07H 13/08 17/04 17/04 A23L 2/00 F (72) Inventor Hirokazu Hosoyama Sagara-cho, Haibara-gun, Shizuoka Prefecture 21 Goddess Itoenai Co., Ltd. (72) Inventor Akio Sugimoto 21 Goddess Sagara-cho, Haibara-gun, Shizuoka Prefecture Itoenai Co., Ltd. (72) Inventor Kozo Nagata 21 Goddess Sagara-cho, Haibara-gun Shizuoka Itoenai Co., Ltd. (72) Inventor Takami Tsunoda 21 Goddess, Sagara-cho, Hara-gun, Shizuoka Itoennai F-term Co., Ltd. (reference) 4B017 LC03 LC04 LK06 4B018 MD07 MD42 ME01 ME03 ME04 4C057 BB02 CC01 DD01 KK02 KK11 4C071 AA02 BB01 BB06 CC12 EE07 FF17 HH09 JJ01 LL01 4C086 AA01 AA02 CA01 EA11 MA01 MA04 NA14 ZA70 ZC20 ZC35 4C088 AB71 AC04 ZA70 ZC20 ZC35

Claims (7)

[Claims] 1. A sugar digestive enzyme inhibitor containing baroneacic acid as an active ingredient. 2. A sugar digestive enzyme inhibitor containing baroneaic acid glycoside as an active ingredient. 3. The baroneaic acid glycoside has the following formula (wherein R is
At least any one of 1 to R4 is a sugar, and R1
The remainder of R4 to R4 is any one of a hydrogen atom, a functional group having 1 or more carbon atoms, and a sugar. ] The sugar digestive enzyme inhibitor of Claim 2 represented by these. [Chemical 1] 4. A blood sugar level increase inhibitor containing, as an active ingredient, either baroneaic acid, baroneaic acid glycoside, or a mixture thereof. 5. An agent for treating and preventing obesity, which comprises any one of baroneaic acid and baroneaic acid glycoside, or a mixture thereof as an active ingredient. 6. A therapeutic / preventive agent for diabetes which comprises, as an active ingredient, any one of baroneaic acid, baroneaic acid glycoside, or a mixture thereof. 7. A healthy food or drink obtained by adding any one of baroneaic acid and baroneaic acid glycoside or a mixture thereof to a food and drink material containing a sugar having an α-glucoside bond.